Literature DB >> 30968303

Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature.

Adel Shalata1,2,3, Michael Edery4, Clair Habib5,6, Jacob Genizi6,7,8, Mohammad Mahroum5,9, Lama Khalaily5, Nurit Assaf6,7,8, Idan Segal6,7, Hoda Abed El Rahim10,11, Hana Shapira5, Danielle Urian10, Shay Tzur12,13, Liza Douiev4,14, Ann Saada15,16.   

Abstract

Primary deficiency of coenzyme Q10 (CoQ10 ubiquinone), is classified as a mitochondrial respiratory chain disorder with phenotypic variability. The clinical manifestation may involve one or multiple tissue with variable severity and presentation may range from infancy to late onset. ADCK3 gene mutations are responsible for the most frequent form of hereditary CoQ10 deficiency (Q10 deficiency-4 OMIM #612016) which is mainly associated with autosomal recessive spinocerebellar ataxia (ARCA2, SCAR9). Here we provide the clinical, biochemical and genetic investigation for unrelated three nuclear families presenting an autosomal form of Spino-Cerebellar Ataxia due to novel mutations in the ADCK3 gene. Using next generation sequence technology we identified a homozygous Gln343Ter mutation in one family with severe, early onset of the disease and compound heterozygous mutations of Gln343Ter and Ser608Phe in two other families with variable manifestations. Biochemical investigation in fibroblasts showed decreased activity of the CoQ dependent mitochondrial respiratory chain enzyme succinate cytochrome c reductase (complex II + III). Exogenous CoQ slightly improved enzymatic activity, ATP production and decreased oxygen free radicals in some of the patient's cells. Our results are presented in comparison to previously reported mutations and expanding the clinical, molecular and biochemical spectrum of ADCK3 related CoQ10 deficiencies.

Entities:  

Keywords:  ADCK3; Coenzyme Q; Mitochondrial disease; Q10 deficiency-4; SCAR9; Spinocerebellar ataxia

Mesh:

Substances:

Year:  2019        PMID: 30968303     DOI: 10.1007/s11064-019-02786-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Coenzyme Q-dependent mitochondrial respiratory chain activity in granulosa cells is reduced with aging.

Authors:  Assaf Ben-Meir; Shlomi Yahalomi; Brit Moshe; Yoel Shufaro; Benjamin Reubinoff; Ann Saada
Journal:  Fertil Steril       Date:  2015-06-11       Impact factor: 7.329

3.  ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic?

Authors:  O Hikmat; C Tzoulis; P M Knappskog; S Johansson; H Boman; P Sztromwasser; E Lien; E Brodtkorb; D Ghezzi; L A Bindoff
Journal:  Eur J Neurol       Date:  2016-04-23       Impact factor: 6.089

4.  Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy.

Authors:  Mike Gerards; Bianca van den Bosch; Chantal Calis; Kees Schoonderwoerd; Klaartje van Engelen; Marina Tijssen; René de Coo; Anneke van der Kooi; Hubert Smeets
Journal:  Mitochondrion       Date:  2010-05-23       Impact factor: 4.160

5.  Heterozygous Mutations in the ADCK3 Gene in Siblings with Cerebellar Atrophy and Extreme Phenotypic Variability.

Authors:  Lubov Blumkin; Esther Leshinsky-Silver; Ayelet Zerem; Keren Yosovich; Tally Lerman-Sagie; Dorit Lev
Journal:  JIMD Rep       Date:  2013-09-19

Review 6.  Human coenzyme Q10 deficiency.

Authors:  Catarina M Quinzii; Salvatore DiMauro; Michio Hirano
Journal:  Neurochem Res       Date:  2006-11-10       Impact factor: 3.996

7.  The Effects of Ascorbate, N-Acetylcysteine, and Resveratrol on Fibroblasts from Patients with Mitochondrial Disorders.

Authors:  Liza Douiev; Devorah Soiferman; Corinne Alban; Ann Saada
Journal:  J Clin Med       Date:  2016-12-22       Impact factor: 4.241

Review 8.  The Value of Coenzyme Q10 Determination in Mitochondrial Patients.

Authors:  Delia Yubero; George Allen; Rafael Artuch; Raquel Montero
Journal:  J Clin Med       Date:  2017-03-24       Impact factor: 4.241

9.  Fast and accurate long-read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2010-01-15       Impact factor: 6.937

10.  The Ensembl Variant Effect Predictor.

Authors:  William McLaren; Laurent Gil; Sarah E Hunt; Harpreet Singh Riat; Graham R S Ritchie; Anja Thormann; Paul Flicek; Fiona Cunningham
Journal:  Genome Biol       Date:  2016-06-06       Impact factor: 13.583

View more
  4 in total

Review 1.  Primary Coenzyme Q10 Deficiency-7 and Pathogenic COQ4 Variants: Clinical Presentation, Biochemical Analyses, and Treatment.

Authors:  Jieqiong Xie; Jiayang Jiang; Qiwei Guo
Journal:  Front Genet       Date:  2022-01-26       Impact factor: 4.599

2.  Multifaceted Analyses of Isolated Mitochondria Establish the Anticancer Drug 2-Hydroxyoleic Acid as an Inhibitor of Substrate Oxidation and an Activator of Complex IV-Dependent State 3 Respiration.

Authors:  Kumudesh Mishra; Mária Péter; Anna Maria Nardiello; Guy Keller; Victoria Llado; Paula Fernandez-Garcia; Ulf D Kahlert; Dinorah Barasch; Ann Saada; Zsolt Török; Gábor Balogh; Pablo V Escriba; Stefano Piotto; Or Kakhlon
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

3.  Primary coenzyme Q10 deficiency due to COQ8A gene mutations.

Authors:  Linwei Zhang; Tetsuo Ashizawa; Dantao Peng
Journal:  Mol Genet Genomic Med       Date:  2020-08-02       Impact factor: 2.183

4.  Microarray and qPCR Analysis of Mitochondrial Metabolism Activation during Prenatal and Early Postnatal Development in Rats and Humans with Emphasis on CoQ10 Biosynthesis.

Authors:  Jana Krizova; Martina Hulkova; Vaclav Capek; Petr Mlejnek; Jan Silhavy; Marketa Tesarova; Jiri Zeman; Hana Hansikova
Journal:  Biology (Basel)       Date:  2021-05-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.